Endostatin is a potent endogenous angiogenesis inhibitor that induces regression of tumors in mice. Neither an extracellular receptor for endostatin nor intracellular signals that result in the regression of tumor vascular beds have been identified. We demonstrate that endostatin, but not angiostatin, at comparable concentrations to those used in in vivo animal trials, rapidly down-regulates many genes in exponentially growing endothelial cells. These include immediate early response genes, cell cycle-related genes, and genes regulating apoptosis inhibitors, mitogen-activated protein kinases, focal adhesion kinase, G-proteincoupled receptors mediating endothelial growth, a mitogenic factor, adhesion molecules, and cell structure components. Suppression of both apoptosis inhibitors and cell proliferation genes may have a limited contribution to the antiangiogenesis process because endostatin induces neither apoptosis nor growth inhibition, unless studied under reduced serum conditions. In contrast, the antimigratory effect of endostatin was rapid and potent even under serum-supplemented con- 
and systemic therapy is not associated with acquired resistance, as mouse tumors do not develop resistance to multiple cycles of endostatin therapy (3, 4) . Tumors produce angiogenesis factors that promote vascularity in areas of new growth. Therefore, angiogenesis inhibitors must elicit potent and profound signals to overcome the combined effects of these factors. In reduced serum conditions, endostatin induces endothelial apoptosis and blocks proliferation and migration induced by vascular endothelial growth factor (VEGF) (5) (6) (7) (8) . In this study, we present evidence that endostatin potently down-regulates many growth-and apoptosis-related genes in exponentially growing endothelial cells, the spectrum of which is similar to that following serum deprivation. However, in serum-supplemented conditions that represent maximal growth stimulation, endostatin is not pro-apoptotic and only slightly reduces proliferation and cell cycle transition. Endostatin appears to trigger gene suppression signals specifically in growing endothelial cells, resulting in a potent antimigratory effect.
Cell culture
Cells were maintained in a 5% CO 2 atmosphere at 37°C. Endothelial cells were prepared from either the aorta (rAE cells) or the pulmonary artery (rPAE cells) of male Wistar rats by collagenase and elastase digestion (9) . Aortic vascular smooth muscle (rVSM) cells were prepared by the explant method (10) . These primary cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The following panel of fibroblast cell lines was generously provided by Dr. John M. Sedivy (Brown University, Providence, R. I.) and cultured in DMEM supplemented with glutamine and 10% calf serum: TGR-1, a nontransformed diploid cell line originally derived from Rat-1 fibroblasts (11); two homozygous c-myc knockout cell lines, HO15.19 and HO16C (12) , derived from their heterozygous parental cells, HET15 and HET16, respectively (13) ; and LACO3 and LACO16, each containing a stable c-myc transgene introduced into HET15 and HET16, respectively (13, 14) . Human stomach adenocarcinoma cells, MKN-1 (JCRB0252), obtained from the Human Science Research Resources Bank (Osaka), were cultured in RPMI 1640 with 10% FBS. Human umbilical vein endothelial cells (HUV-EC-C, CRL-1730) obtained from American Type Culture Collection (Manassas, Va.) were cultured in Ham's F12K medium with 2 ml of glutamine, 0.1 mg/ml heparin, 0.05 mg/ml endothelial cell growth supplement, and 10% FBS. Human adult dermal microvascular endothelial (hADM) cells were purchased from Cell Systems (Kirkland, Wash.) and cultured with the CS-C Medium Kit supplemented with VEGF, basic fibroblast growth factor (bFGF), heparin, endothelial cell growth supplement, and 20% FBS. Endothelial origin was confirmed by cobblestone morphology and by immunocytochemistry with antibodies to factor VIII-related antigen and rat endothelial cell antigen (Sanbio BV, Uden, The Netherlands).
Quantification of mRNAs by using two reverse transcriptase (RT)-PCR methods
For quantification of rat c-myc, max, integrin ␣v, ␣-tubulin, and ␤-tubulin mRNA, we used the following two methods: 1) a real-time quantitative RT-PCR method based on the TaqMan fluorescence method with the ABI Prism 7700 Sequence Detection System (PE Applied Biosystems, Foster City, Calif.) and 2) a LightCycler (Roche Molecular Biochemicals, Mannheim, Germany) PCR protocol in which fluorescence emission resulting from binding of SYBR Green I dye to amplified products could be detected and measured. Both the ABI Prism 7700 Sequence Detection System and the LightCycler showed statistically identical results when we quantified transcripts of c-myc, max, integrin ␣v, ␣-tubulin, and ␤-tubulin. Therefore, subsequent analyses of genes regulated by endostatin and angiostatin were performed with the LightCycler. Total RNA was extracted by using RNA zol B (TEL-TEST, Friendswood, Tex.) and cDNA synthesized with a First-Strand cDNA Synthesis Kit (Amersham Pharmacia Biotech, Piscataway, N.J.). Quantification of c-myc and max using the TaqMan fluorescence method was performed as described previously (9) . Rat integrin ␣v, ␣-tubulin, and ␤-tubulin were amplified (integrin ␣v: forward primer 5Ј-GCAAGACTGTCCTGTGCATTTAAG-3Ј, reverse primer 5Ј-AGTTGAGTTCCAGCCTTCTTCG-3Ј, and TaqMan probe 6FAM-AGAAAACCAAACCCGGCAGGTGGT-TAMRA; ␣-tubulin: forward primer 5Ј-TGTGGTCCCCAAAGAT-GTCA-3Ј, reverse primer 5Ј-AAACTGGATGCTGCGCTTG-3Ј, and TaqMan probe 6FAM-TGCTGCCATTGCCACCATCAAGA-TAMRA; ␤-tubulin: forward primer 5Ј-GCAGATGCTCAACGTG-CAGA-3Ј, reverse primer 5Ј-GGCCGTCTTCACATTGTTGG-3Ј, and TaqMan probe 6FAM-CAAGAACAGCAGCTACTTCGTG-GAATGGA-TAMRA) and the reaction produced 88 bp, 45 bp, and 53 bp products, respectively. LightCycler was also used to quantify mRNA. Each amplification reaction (DNA Master SYBR Green I: Roche Diagnostics) contained 50 nM template cDNA, 0.5 M primer DNA, and 4 mM MgCl 2 . TaqStart antibody (CLONTECH, Palo Alto, Calif.) was used to prevent generation of nonspecific amplification products. The sequences of each set of primers are listed in Table 1 . Quantification of c-myc using the LightCycler was performed by using two sets of primers, each amplifying either exon 2 or exon 3. After the completion of each extension step (72°C), the fluorescence of each sample was measured at 82°C to exclude any possible nonspecific reactions. After the amplification was finished, the products were subjected to a temperature gradient from 65 to 95°C at 0.2°C/s with continuous fluorescence monitoring to produce a melting profile of the products. The fluorescence data were quantitatively analyzed by using serial dilution of control samples included in each reaction to produce a standard curve. For verification of the melting curve results, the PCR reactions were examined by 1.5% agarose gel electrophoresis.
Western blot analyses
Quantitative Western blotting was performed as previously described (9) . Confluent cells (5 ϫ10 6 cells/dish) were treated with and without 10 Ϫ6 M endostatin for 16 h. Extracted proteins were separated on an 8% SDS-polyacrylamide gel and transferred to Hybond ECL nitrocellulose membranes (Amersham). Primary incubations were with the following primary antibodies at 4°C overnight: rabbit polyclonal antibody against human Max p21/p22 (1:500; Santa Cruz Biotechnology, Santa Cruz, Calif.), mouse monoclonal antibody against ␣-tubulin (1:1,000; Sanbio BV), mouse monoclonal antibody against ␤-tubulin (1:1,000; Chemicon International, Temecula, Calif.), mouse monoclonal antibody against Bcl-2 (1:500; Transduction Laboratories, Lexington, Ky.), mouse monoclonal antibody against mitogen-activated protein kinase MAPK-1 (1:5000; Transduction Laboratories), rabbit polyclonal antibody against integrin ␣ v (1:100; Chemicon International), and mouse monoclonal antibody against integrin ␤3 (1:250; Transduction Laboratories). The secondary antibody (donkey anti-rabbit immunoglobulin G or sheep anti-mouse immunoglobulin horseradish peroxidase, 1:500; Amersham) was incubated for 1 h, and exposure was performed by using an ECL kit (Amersham).
Secretion of endothelin-1 from endothelial cells
rAE cells plated in 3.5 cm dishes were pretreated with endostatin, or were not pretreated with endostatin, for 16 h, after which replacement fresh serum-free DMEM was used for 4 h. Endothelin-1 concentrations in the conditioned media were measured by using an Endothelin-1 ELISA system (Amersham) according to the manufacturer's protocol.
Cell cycle analysis and cell proliferation assay
Exponentially growing endothelial cells that received treatment with or without endostatin, or were deprived of serum for 14 h, were harvested by trypsinization and stained with propidium iodide (50 g/ml in 0.1% Triton X-100/0.1% sodium citrate, pH 7.0) in subdued light for 15 min at 4°C. Cellular fluorescence signals were recorded with an FACS Calibur flow cytometer (Becton Dickinson, Mountain View, Calif.) using the CELL QUEST software program. The 72 h cell proliferation assays were performed as previously de-scribed (3) without reducing serum or growth factor supplementation. Cells were plated in 12-well dishes at a density of 1.5 ϫ 10 4 cells/well and were incubated for 72 h in the presence or absence of endostatin. Cells were released from culture dishes by trypsinization and were counted by using a Sysmex CDA-500 Autoanalyzer (Toa Medical Electronics, Kobe, Japan).
Detection of apoptosis
To detect nucleosomal ladders, fragmented cellular DNA was extracted by using Nonidet P-40 lysis, fractionated on a 1.6% agarose gel and stained with ethidium bromide (14 -16). Cells were also stained for free 3Ј-hydroxyl ends of DNA fragments with dUTP-fluorescein isothiocyanate by using an APO-DIRECT apoptosis detection kit (PharMingen, San Diego, Calif.) and counterstained for total DNA content with propidium iodide. Stained cells were then analyzed with an FACS Calibur flow cytometer as described previously (10) . Caspase-3 activity was assayed by using the CaspACE Assay System, Colorimetric (Promega, Madison, Wis.) as described earlier (10) . Fluorescence of Fura-2-loaded cells was measured by using continuous rapid alternating excitation from dual monochromators (340 and 380 nm) and emission at 510 nm (CAF-100, Japan Spectroscopic, Tokyo). The readings were converted to [Ca 2ϩ ] i as previously described (17) .
Determination of intracellular free

Determination of kinase activities and measurement of cAMP
PathDetect Trans-Reporting Systems (Stratagene, La Jolla, Calif.) were used to measure p42/p44 MAPK, p38 kinase, c-Jun N-terminal kinase (JNK), and cyclic AMP-dependent protein kinase (PKA) activities. The system includes the fusion activator plasmids that consist of the DNA binding domain of the yeast GAL4 fusion activator (pFR-Luc) and the activation domain of the transcription factor, Elk1, CHOP, c-Jun, and CREB (pFA2-Elk1, pFA-CHOP, pFA2-cJun, pFA2-CREB). Cells plated in 96-well plates were cotransfected with each pFA2 plasmid (50 ng each/well), pFR-Luc reporter plasmid (1 g each/well), and pRL-TK vector (1 g each/ well) (Promega), which expresses renilla luciferase as an internal control. Transient transfections were performed with the synthetic cationic liposome (ϩ)-N,N-bis (2-hydroxyethyl)-N-methyl-N- [2,3-di(tetradecanoyloxy) propyl]ammonium iodide according to instructions provided by the supplier (Promega) and were modified to use transferrin-receptor operated transfer as described earlier (17, 18) . The cells were incubated for 48 h after transfection in DMEM containing 
10% FBS and were further incubated with endostatin for 6 h, after which firefly and renilla luciferase activities were measured via the Dual Luciferase Reporter Assay System (Promega) in a single-tube assay format using MicroLumat Plus (EG&G Berthold, Wildbad, Germany). The firefly luciferase activity of each sample was normalized to an internal reference standard of renilla luciferase activity. The intracellular cAMP concentration of endothelial cells before and 15 min after endostatin treatment was measured by using a cAMP enzyme immunoassay (EIA) system (Amersham).
Monolayer-denuding cell migration assay
Cells were cultured in collagen-coated 3.5 cm dishes (Iwaki, Chiba, Japan) to confluence, incubated for 3 days, and then received pretreatment with or without endostatin for 16 h. Several areas ϳ300 m wide were denuded with a sterile single-edged surgical blade (Surgical Blade No. 11, Stainless Steel, Feather Safety Razor, Osaka, Japan). Phase-contrast photomicroscopy at 100 ϫ magnification was performed immediately and 4, 6, 8, 16 , and 24 h after denudement at four distinct sites, with the center of the wound (marked with a scratch) in the middle of each frame. The mean distance from a defined line in the middle of the wound to the nuclei of 20 furthest-migrating cells in a particular frame was measured by Adobe Photoshop 5.0 software after incorporation of photographs using GT8000 (Epson, Tokyo, Japan) and then normalized to a standard field width. Distance migrated was calculated from the mean distances in successive frames of a particular field. Repeated measurements of the same area generated standard deviations in the range of 1-4%.
Statistical analysis
All values were given as means Ϯ se. Statistical analysis was performed with Student's t test or Wilcoxon's rank sum test. P values less than 0.05 were considered statistically significant.
RESULTS
Endostatin down-regulated genes involved in proliferation, apoptosis, and cell migration
Recombinant endostatin was added to exponentially growing rAE cells. Endostatin treatment down-regulated the mRNA levels of c-fos, c-myc, and max in a timedependent (1-6 h) and dose-dependent (10
Ϫ8
-10 Ϫ6 M) manner. Incubation with 10 Ϫ6 M endostatin down-regulated the mRNA of these genes to a greater extent than did serum deprivation (Fig. 1) . Endostatin treatment down-regulated mxi1, bcl-2, bcl-X(L), and bad but did not alter the expression of other genes such as bax, p53, cdc25A (Fig. 1) , or p38 kinase (data not shown). Endostatin also down-regulated cdc25B, MAPK-1 and MAPK-2, ␣-tubulin, ␤-tubulin, integrin ␣v, integrin ␤3, AT 1 and AT 2 (angiotensin II receptors), ET B (endothelin receptor type B), and preproendothelin-1. Endostatin did not alter gene expression in quiescent rAE cells, exponentially growing rVSM cells, or TGR-1 fibroblasts (data not shown). The results of angiostatin treatment were in marked contrast to those for endostatin. Angiostatin treatment downregulated c-fos, MAPK-2, and bcl-2 and up-regulated mxi1, bad, bax, p53, ET B , and preproendothelin-1 (Fig. 2) .
The ability of endostatin to down-regulate gene expression is not restricted to rAE cells but was also observed in hADM cells (Fig. 3A) as well as in rPAE cells and HUV-EC cells (data not shown). In hADM cells, endostatin treatment down-regulated the expression of c-myc, max, mxi1, integrin ␣v, integrin ␤3, ET B , preproendothelin-1, PECAM-1, FAK (focal adhesion kinase), and cadherin-5. The magnitude of down-regulation of most Figure 1 . Effects of endostatin on the mRNA of growth-, apoptosis-, and mitogenesis-related genes in growing endothelial cells. Total RNA was extracted from exponentially growing primary rAE cells treated with recombinant mouse endostatin in 10% FBS-DMEM for 4 h, or placed in 0% FBS-DMEM for 4 h. First-strand cDNA was generated by reverse transcription and was subjected to real-time quantitative PCR with the LightCycler. Data represent the mean Ϯ se of six determinations of the percentage of mRNA copies relative to untreated growing cells. *P Ͻ 0.01 and **P Ͻ 0.005 vs. control. of these genes was more pronounced in hADM cells than in rAE cells, even when the culture media were supplemented with VEGF, bFGF, and 20% FBS.
Despite rapid mRNA down-regulation, endostatin treatment did not significantly reduce the protein levels of many constitutively expressed genes in hADM cells. Quantitative Western blot analyses revealed a minimal inhibitory effect on Max p21/p22, whereas there was no appreciable change in p42/p44 MAPK-1, ␣-tubulin, ␤-tubulin, or Bcl-2. However, endostatin treatment suppressed the protein levels of integrin ␣v and integrin ␤3 (Fig. 3B) . Pretreatment with endostatin decreased the amount of endothelin-1 secreted by rAE cells into culture media in a dose-dependent manner (10 Ϫ8 -10 Ϫ6 M) (Fig. 3C ).
Endostatin increased [Ca
2؉ ] i and cAMP activity
Endostatin induced a sustained increase in the [Ca 2ϩ ] i in a dose-dependent manner (10 Ϫ8 -10 Ϫ6 M) (Fig. 4A) . The magnitude of increase in [Ca 2ϩ ] i was greater after VEGF treatment. The increase in [Ca 2ϩ ] i by endostatin was blocked by pretreatment with either nicardipine or EGTA. However, neither nicardipine nor W7 (a Ca 2ϩ / calmodulin inhibitor) blocked the ability of endostatin to down-regulate gene expression. Endostatin treatment activated cAMP-dependent protein kinase (Fig.  4B, left panel) and increased intracellular cAMP in a dose-dependent manner (Fig. 4B, right panel) . Endostatin treatment did not alter the activity of p42/p44 ERK/MAP kinase, p38 kinase, or JNK.
Endostatin had a weak growth-inhibitory influence on endothelial cells
Flow cytometry, caspase 3 determination, and TUNEL staining showed that endostatin did not induce apoptosis in rAE cells or hADM cells cultured in 10% FBS. Yet endostatin treatment did reduce the percentage of cells in S phase (Fig. 4C) . The 72 h proliferation assays (3) revealed the weak growth-inhibitory effect of endostatin on exponentially growing rAE, HUV-EC, and hADM cells but not on rPAE (Fig. 4D) , TGR-1, or rVSM cells or a human gastric cancer cell line, MKN-1.
Endostatin arrested endothelial cell migration
The antimigratory effect of endostatin and angiostatin was evaluated with a monolayer-wounding protocol in which cells migrate from a confluent area onto a denuded area. Cell proliferation assays demonstrated that endostatin did not affect the growth rate of any cells during the initial 24 h. [ 3 H]Thymidine incorporation revealed that confluent cultures of hADM or rAE cells that are denuded do not proliferate during the first 8 h. Therefore, repopulation within 8 h is due solely to cell migration. Endostatin inhibited the migration of rAE cells (Fig. 5A ) and rPAE cells (data not shown) in a dose-dependent manner. After endostatin pretreatment, rAE cells and rPAE cells migrated more slowly than did controls. A minority of treated cells migrated, whereas a majority of control cells migrated rapidly until the denuded area was confluent (Fig. 5B) . Arrested cells regained the ability to migrate when endostatin was removed from the culture medium. Endostatin did not inhibit the migration of nonendothelial cells such as TGR-1 (Fig. 6B) or rVSM cells (data not shown). hADM cells cultured with complete growth supplementation migrated faster than did rAE cells yet were still subject to migration arrest by endostatin treatment (Fig. 5C ). When pretreated with 10 Ϫ6 M endostatin, hADM cells appeared almost unable to migrate (Fig. 5D) . In contrast, angiostatin did not show an antimigratory effect on endothelial cells.
c-myc down-regulation correlated with the arrest of cell migration
A c-myc-expressing plasmid (pSPT-Myc) was transiently transfected into hADM cells by using transferrin receptor-operated transfer (9) , and the resulting elevation in c-myc expression was not suppressed by endostatin treatment. Transfection of pSPT-Myc resulted in an increased migratory rate, and endostatin treatment failed to arrest migration of hADM cells transfected with pSPT-Myc (Fig. 6A) . Overexpression of max or mad down-regulated E-box transcription because Max-Mad heterodimers competitively inhibited Myc-Max heterodimers. Transfection of pSP-Max or pSP-Mad resulted in a significant decrease in the migration rate of hADM cells (Fig. 6A) .
A panel of isogenic fibroblast cell lines with differential c-myc expression levels was used to investigate the role of endogenous c-myc in cell migration. We compared two c-myc null cell lines obtained by gene targeting of the endogenous c-myc copies (myc Ϫ/Ϫ ) (12) to their isogenic diploid parental cell line TGR-1 (myc ϩ/ϩ ) (11), and two derivatives, LACO3 and LACO16, which stably overexpress c-myc (myc Ϫ/ϩ,ϩϩ ) (13, 19) . The two myc Ϫ/Ϫ cell lines showed a reduced migratory rate compared with TGR-1 cells (Fig. 6B) . The c-myc transgene-expressing cells (myc Ϫ/ϩ,ϩϩ ) displayed an increased migratory rate (Fig. 6B) . Fig. 1 . B) Endostatin minimally altered protein levels of constitutively expressed genes but reduced the levels of adhesion molecules. Protein samples (10 g) from hADM cells with (E) or without (C) 10 Ϫ6 M endostatin pretreatment were subjected to Western blot analysis. Western blotting was repeated three times with qualitatively similar results. C) Endostatin inhibited the secretion of endothelin-1 from rAE cells. Growing rAE cells with or without endostatin pretreatment for 16 h received replacement serum-free DMEM and were further incubated for 4 h. Endothelin-1 levels in conditioned media were measured with an EIA. Each column represents mean Ϯ se (n ϭ 4). *P Ͻ 0.05 and **P Ͻ 0.01 vs. control.
DISCUSSION
The present results demonstrate that a 4 h incubation with recombinant endostatin, at comparable concentrations used in in vivo animal trials (3), down-regulates a variety of genes in growing endothelial cells. Immediate early genes, such as c-fos and c-myc, were down-regulated simultaneously with max. Other genes closely related to cell growth, such as cdc25B, MAPK-1, MAPK-2, preproendothelin-1, ET B receptor, and AT 1 receptor, were also down-regulated. Endostatin down-regulated genes encoding for cell structure components such as ␣-and ␤-tubulin, which polymerize into microtubules that form a network of essential structures including mitotic spindles (20) . Because the downstream consequences of endostatin treatment on gene expression are similar to those following serum deprivation, we initially speculated that endostatin exerts an antiangiogenesis effect by eliciting quiescence signals, rapidly shifting growing endothelial cells into G 0 . However, our results show B) The addition of endostatin to rAE cells grown in 10% FBS increased PKA activity. Cells were cotransfected with pFR-Luc, pFA2 plasmid (GAL4), and pRL-TK (renilla luciferase). Transcriptional activity of the GAL4 plasmid after incubation with or without endostatin was analyzed by using firefly luciferase as a reporter gene normalized with renilla luciferase as an internal control (left panel). Intracellular cAMP concentration was also measured by using an EIA (right panel). Each column represents mean Ϯ se (n ϭ 8). *P Ͻ 0.01 and **P Ͻ 0.001 vs. control. C) Endostatin reduced the percentage of cells in S phase. Growing endothelial cells with or without endostatin treatment in 10% FBS or deprived of serum for 14 h were stained with 50 g/ml propidium iodide and analyzed with an FACS Calibur flow cytometer (Becton Dickinson). Representative results from four independent experiments are shown. D) Endostatin inhibited endothelial cell proliferation. Exponentially growing endothelial cells were treated with or without endostatin, and the cell population was counted after 72 h. Each point with a bar represents the mean Ϯ se (n ϭ 6). *P Ͻ 0.05 and **P Ͻ 0.01 vs. control.
that endostatin has only a weak growth-inhibitory effect on endothelial cells. Quiescence is therefore unlikely to be the mechanism for the potent in vivo antiangiogenesis activity of endostatin.
Several explanations may account for the inability of endostatin to arrest endothelial cell proliferation. First, the rapid mRNA down-regulation of constitutively expressed genes such as max or MAPK-1 was not immediately followed by a decrease in their protein levels. Second, growth signals may be mediated by changes in protein phosphorylation and therefore not influenced by changes in protein levels. For example, our results show that endostatin did not alter p42/p44 ERK/ MAPK or p38 kinase activity. Third, reduced c-myc levels may not markedly inhibit cell growth because c-myc heterozygous knockout cells (myc Ϫ/ϩ ) exhibit only a 2 h delay in the G 1 to S transition (13) , and c-myc null cell lines (myc Ϫ/Ϫ ) still grow (12) . Fourth, c-myc suppression itself may not cause down-regulation of other growth-associated genes. We have confirmed a previous report (21) that the expression of proposed "c-myc target" genes, such as cdc25A and p53 (22, 23) , that are up-regulated by c-myc overexpression are unchanged in c-myc null cells.
Endostatin dramatically arrested the migration of endothelial cells. This effect was especially profound in hADM cells, which normally migrate faster than do endothelial cells derived from larger vessels. An ideal angiogenesis inhibitor must offset the combined effects of growth factors and other angiogenesis mediators that are vigorously produced by tumors. In the present study, the ability of endostatin to arrest endothelial cell migration was undiminished even when cells were maximally stimulated with nutrients and growth factors. Endostatin also inhibited genes associated with cell migration and angiogenesis, such as endothelin-1, ET B receptor, integrin ␣v, integrin ␤3, FAK, cadherin-5, and PECAM-1. Endothelin-1, for example, is an endothelial cell growth factor (18) that mediates migratory and angiogenic effects via the ET B receptor (24) . The cell adhesion molecules integrin ␣v␤3 and integrin ␣v␤5, expressed on the surface of endothelial cells, mediate interactions with the extracellular matrix, an important process during angiogenesis. Although the arrest of endothelial cell migration is certainly multifactorial, our results suggest that one intracellular factor is the down-regulation of c-myc expression. Transfection of a c-myc-expressing vector completely abrogated the anti- migratory effect of endostatin, whereas antagonism of c-Myc function at E-box promoters by overexpressing max or mad resulted in a reduced endothelial cell migration rate. In addition, c-myc null fibroblasts showed a reduced migration rate compared with their isogenic parental cells, again suggesting a role for c-myc in cell migration. It should be noted, however, that neither overexpression of max and mad nor c-myc gene knockouts completely arrested migration, suggesting that cells can still migrate in the absence of c-myc and that c-myc is not uniquely responsible for endostatininduced migration arrest. Taken together, the results indicate that c-myc is involved in both baseline cell migration and endostatin-induced inhibition of endothelial migration, although down-regulation of other migration-associated genes may likely contribute to the potent antimigratory effect of endostatin.
The intracellular events immediately following endostatin stimulation leading to the down-regulation of genes remain unknown. Because endostatin increased [Ca 2ϩ ] i via the influx of extracellular Ca 2ϩ and activated PKA, signals triggered by endostatin may be transmitted via an as yet unidentified cell surface receptor. Limited mechanistic insights into the action of endostatin have been previously described. Endostatin has been shown to antagonize both the cell cycle progression and the migration of quiescent human umbilical endothelial cells induced by bFGF (5, 8) and to cause apoptosis of FGF-treated endothelial cells by suppressing bcl-2 without affecting bax (6) or by inducing tyrosine kinase activity (7) . Although these data are consistent with ours, down-regulation of apoptosis inhibitors would not cause the massive apoptotic elimination of tumor vascular beds in in vivo endostatin therapy. Endostatin-induced apoptosis and bcl-2 suppression were blocked by the addition of serum or endothelium-derived survival factors to the culture medium (data not shown). Repeated use of any agent that induces massive endothelial apoptosis or complete growth arrest could result in systemic vascular diseases, including ischemic heart disease. Such side effects have not been previously reported with endostatin. Arrest of endothelial cell migration more clearly explains the mechanism of tumor regression. In contrast to endostatin, angiostatin showed a limited gene suppression profile and was devoid of an ability to arrest endothelial cell migration. This difference suggests a different mechanism of antiangiogenesis for the two factors. Angiostatin has been shown to bind to the ␣␤ subunits of ATP synthase on the cell surface, which may result in tumor regression by depleting the ATP energy required for angiogenesis (25) . Therefore, the action of angiostatin may not require the down-regulation of the number of genes as seen with endostatin. To date, no bioactive substance is known to exert such a novel antimigratory signal.
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